Evidence map›Paper›PMID 36536171›Full record

SynthesisAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2023

Very Short Versus Longer Dual Antiplatelet Treatment After Coronary Interventions: A Systematic Review and Meta-analysis.

Grigorios Tsigkas, Anastasios Apostolos, Aikaterini Trigka, Dimitrios Chlorogiannis, Konstantinos Katsanos, Konstantinos Toutouzas, Dimitrios Alexopoulos, Emmanouil S Brilakis, Periklis Davlouros

Open access · hybridAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in American journal of cardiovascular drugs : drugs, devices, and other interventions, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 3 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 3 syntheses or guidelines pooled it, 20 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Grigorios Tsigkas *Department of Cardiology, Faculty of Medicine, University of Patras, University Hospital of Patras, Patras, Greece. gregtsig@hotmail.com.
Anastasios Apostolos *Department of Cardiology, Faculty of Medicine, University of Patras, University Hospital of Patras, Patras, Greece.
Aikaterini TrigkaDepartment of Cardiology, Faculty of Medicine, University of Patras, University Hospital of Patras, Patras, Greece.
Dimitrios ChlorogiannisDepartment of Cardiology, Faculty of Medicine, University of Patras, University Hospital of Patras, Patras, Greece.
Konstantinos KatsanosDepartment of Interventional Radiology, Faculty of Medicine, University of Patras, University Hospital of Patras, Patras, Greece.
Konstantinos ToutouzasFirst Department of Cardiology, Medical School, National and Kapodistrian University of Athens, Hippokration General Hospital, Athens, Greece.
Dimitrios AlexopoulosSecond Department of Cardiology, Medical School, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece.
Emmanouil S BrilakisMinneapolis Heart Institute and Minneapolis Heart Institute Foundation, Minneapolis, MN, USA.
Periklis DavlourosDepartment of Cardiology, Faculty of Medicine, University of Patras, University Hospital of Patras, Patras, Greece.
General University Hospital of Patras · GRUniversity of Patras · GRNational and Kapodistrian University of Athens · GRMinneapolis Heart Institute Foundation · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVery short (≤ 3 months) duration of dual antiplatelet therapy (VSDAPT) has recently been proposed after percutaneous coronary intervention (PCI) with drug-eluting stent (DES).

objectivesThe aim of this systematic review and meta-analysis was to compare very short versus > 3 months' duration of dual antiplatelet treatment (DAPT) in patients undergoing PCI with DES, focusing on ischemic and bleeding events.

methodsThree major databases (Medline, Cochrane Central Register of Controlled Trials, and Scopus) were screened for eligible randomized controlled trials (RCTs). The primary endpoint of our meta-analysis was the incidence of net adverse clinical events (NACE), as defined per trial, while secondary endpoints were major adverse cardiovascular events (MACE), all-cause and cardiovascular mortality, myocardial infarction, stroke, stent thrombosis, repeat revascularization, and major bleeding.

resultsWe included eight RCTs with a total of 41,204 patients; 20,592 patients were allocated to VSDAPT and the remaining 20,612 patients were randomized to a longer DAPT period. The abbreviated regimen significantly reduced NACE (odds ratio [OR] 0.83, 95% confidence interval [Cl] 0.74-0.95) and major bleeding (OR 0.71, 95% Cl 0.61-0.82), without affecting mortality or ischemic events (stroke, myocardial infarction, revascularization, and stent thrombosis).

conclusionsVSDAPT significantly decreased the odds of NACEs and major bleeding by 17% and 29%, respectively, without increasing ischemic events. Thus, VSDAPT could be well tolerated and feasible after PCI with DES. CLINICAL TRIALS REGISTRATION: Open Science Framework (10.17605/OSF.IO/4H2JB) Very short-term DAPT significantly reduces NACE and major bleedings, without affecting mortality and ischemic events (MACE, MI, stroke, stent thrombosis and revascularization). CI confidence intervals, DAPT dual antiplatelet therapy, DES drug-eluting stents, MACE major adverse cardiovascular events, MI myocardial infarction, NACE net adverse clinical events, OR odds ratio, PCI percutaneous coronary interventions.

Indexed as

Coronary Artery DiseaseDrug-Eluting StentsMyocardial InfarctionPercutaneous Coronary InterventionStrokeThrombosisDrug Therapy, CombinationHemorrhageHumansPlatelet Aggregation InhibitorsRandomized Controlled Trials as TopicTreatment OutcomePlatelet Aggregation Inhibitors

Identifiers

PMID36536171
PMCPMC9845152
OpenAlexW4312019588

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.